Patent 6,770,660 Claims Scope and U.S. Patent Landscape for Tirofiban Bolus-Plus-12-to-72-Hour IV Infusion
United States Patent 6,770,660 covers a specific intravenous (IV) dosing regimen for tirofiban (or a salt) to inhibit platelet aggregation, including a bolus of about 25 μg/kg followed by an IV infusion of about 0.15 μg/kg/min for 12 to 72 hours. Dependent claims narrow to tirofiban hydrochloride and to specific infusion windows. A parallel independent method claim targets reduction of acute coronary syndrome (ACS) risk using the same dosing parameters. The estate’s practical enforceability in the U.S. hinges on whether an accused product or method practice matches the dosing ranges and route/timing elements.
What patents protect tirofiban bolus 25 μg/kg followed by 0.15 μg/kg/min infusion for 12–72 hours?
Core claim structure: the patent is a method-of-use/dosing regimen claim with three gating limitations.
What are the three infringement “gates” in claim 1?
- Patient and indication: “inhibiting platelet aggregation in a patient in need thereof.”
- Route and schedule:
- Bolus injection of tirofiban (or a salt) about 25 μg/kg.
- After the bolus, IV infusion for between about 12 hours and about 72 hours.
- Dose rate during infusion: infusion about 0.15 μg/kg/min.
A maker or prescriber can avoid literal coverage by changing any of these elements outside the “about” ranges, or by using a different route/schedule that falls outside the claimed “bolus then infusion” timing architecture.
What do dependent claims add?
- Claim 2: specifies tirofiban hydrochloride as the salt form.
- Claim 3: fixes bolus amount to 25 μg/kg (not just “about”).
- Claim 4: restricts infusion window to 12–72 hours (already present in claim 1) but as a narrower dependent scaffold.
- Claim 5: further narrows infusion window to 18–72 hours.
- Claim 6: ACS risk reduction claim using the same bolus/infusion parameters and tirofiban (or salt).
Claim 6’s legal effect
Claim 6 is a separate independent method claim with the same dosing regimen limitations but different therapeutic purpose: “reducing the risk of acute coronary syndrome in a patient at risk.” In litigation, that means the plaintiff can pursue different theories of patient “need” or “risk” even if platelet-aggregation inhibition overlaps clinically.
How broad are the “about” ranges for 25 μg/kg and 0.15 μg/kg/min?
Featured snippet answer: the claim uses “about” rather than exact numbers, so the scope depends on the intrinsic record and claim construction.
Practical scope drivers for “about”
- Bolus (“about 25 μg/kg”): alters the infringement risk for any protocol using a nearby nominal dose.
- Infusion rate (“about 0.15 μg/kg/min”): is a key numeric lever; even small changes in infusion rate can be argued as moving outside the “about” tolerance.
- Infusion duration (“about 12–72 hours”): creates a potential design-around by shortening duration below ~12 hours or extending beyond ~72 hours.
- “After the bolus injection” sequencing: pre-loading or different timing can create non-infringement arguments if the sequence is not “bolus then infusion” as claimed.
Dependent claim precision and enforcement leverage
Dependent claims that recite exact “25 μg/kg” (claim 3) and longer infusion start windows (claim 5: 18–72 hours) provide narrower footholds. If the asserted protocol differs from claim 1 only slightly, plaintiffs often plead dependent claims in the alternative to capture exact-dose practice or specific infusion start timings.
When does U.S. Drug Patent 6,770,660 lose exclusivity?
Featured snippet answer: Patent 6,770,660 expires based on its U.S. filing and any PTA, and any Hatch-Waxman exclusivity is separate. Exclusivity timing cannot be stated from the claim text alone.
What is the Orange Book status of tirofiban products tied to this dosing regimen?
Featured snippet answer: Orange Book listings and linkages to 6,770,660 cannot be determined from the claim text alone.
How many patents cover tirofiban platelet aggregation inhibition dosing regimens in the U.S.?
Featured snippet answer: the claim text supports this patent as a regimen-specific method, but the total count of overlapping U.S. patents cannot be computed without querying the U.S. patent family and Orange Book/patent litigation databases.
Which companies are challenging or launching around tirofiban regimen patents?
Featured snippet answer: company-specific challenge and launch positions require the actual U.S. patent family landscape, assignments, and any Paragraph IV or § 505(b)(2) litigation records tied to 6,770,660.
How does tirofiban dosing in 6,770,660 compare with other tirofiban regimens in practice?
Featured snippet answer: 6,770,660 is a specific bolus + infusion scheme with a defined dose rate and duration window; design-arounds generally target either the infusion duration start point, infusion rate, or salt formulation.
Technical contrast points used in design-around arguments
- Infusion duration: protocols outside 12–72 hours or outside 18–72 hours (for claim 5) can avoid dependent claim coverage.
- Infusion rate: any regimen at a different mg/kg/min nominal rate can be positioned as outside “about 0.15 μg/kg/min.”
- Bolus strategy: omission of a bolus or use of a different bolus dose can avoid the bolus limitation.
- Salt form: claim 2 requires tirofiban hydrochloride; other salt forms can avoid claim 2 while still potentially infringing claim 1 if “tirofiban or a salt thereof” is satisfied.
What formulations are protected by 6,770,660?
Featured snippet answer: 6,770,660 protects dosing method claims, not a drug product formulation in the typical “composition” sense.
Salt coverage
- Claim 1 covers tirofiban or a salt thereof.
- Claim 2 restricts to tirofiban hydrochloride, which narrows salt scope for any assertion that is limited to the dependent claim.
What manufacturing or administration methods would be blocked by 6,770,660?
Featured snippet answer: practices that administer tirofiban with the claimed route and dosing timing.
Because the claim is a method for inhibiting platelet aggregation and reducing ACS risk, the relevant “practice” is the clinician’s dosing protocol and administration workflow. Manufacturers can still face exposure indirectly through training, labeling, and protocol-driven distribution, depending on enforcement posture.
Routes and administration mechanics that align with the claim
- Bolus injection followed by continuous IV infusion.
- Dosing expressed in μg/kg and μg/kg/min, implying weight-based calculation and pharmacologic monitoring aligned with infusion pump delivery.
What patent litigation affects 6,770,660?
Featured snippet answer: litigation status requires a docket-level check (district court, ITC, appellate) for this patent number; the claim text alone cannot establish enforcement history.
Is 6,770,660 enforceable against generic tirofiban after loss of product exclusivity?
Featured snippet answer: even when product exclusivity ends, an unexpired method-of-use patent can block generic entry if the generic’s label or administration guidance induces infringement of the regimen.
The key risk vector is whether:
- the generic’s prescribing information and clinical protocol align with the bolus/infusion parameters of claims 1 and 6, and
- the generic is sued for induced infringement (or if direct infringement is attributed to medical providers).
How strong is the patent estate for tirofiban dosing regimens like this one?
Featured snippet answer: strength cannot be rated from the claim text alone because it depends on claim construction history, prosecution record, whether the dosing parameters were previously disclosed, and whether related family members cover the same regimen.
How this particular patent’s claim format affects strength
- Narrow numeric anchors (25 μg/kg bolus; 0.15 μg/kg/min infusion) increase prior-art matching risk but also increase “clean” design-around options.
- Broad therapeutic framing (“patient in need,” “reduce ACS risk”) can be challenged if prior art already describes platelet inhibition or ACS management with tirofiban.
- Dependent claim tethering to tirofiban hydrochloride and infusion windows adds fallback positions for plaintiffs.
What generic entry risks exist for tirofiban using bolus-plus-infusion protocols?
Featured snippet answer: the generic entry risk is highest where the generic’s approved labeling or standard clinical protocol for ACS/platelet inhibition uses a bolus plus infusion that falls within the claimed ranges.
Common risk scenarios
- If generic labeling includes dosing instructions matching the claims, the label becomes a central infringement exhibit.
- If protocols used in trials or guidelines map onto the same dosing regimen, induced infringement theories may strengthen.
Geographic coverage: is this U.S. patent part of a broader family?
Featured snippet answer: family scope cannot be determined from the claim text alone.
A dosing regimen patent typically has at least one foreign counterpart if it was considered commercially important across major markets, but exact jurisdictions require family data.
Claim-by-claim scope map for 6,770,660
| Claim |
Protected method |
Hard limitations |
Design-around levers |
| 1 |
Inhibit platelet aggregation |
Bolus of tirofiban (salt) ~25 μg/kg + IV infusion ~0.15 μg/kg/min for ~12–72 hours |
Change bolus dose, infusion rate, infusion duration, or omit bolus/alter sequence/route |
| 2 |
Claim 1 with specific salt |
tirofiban hydrochloride |
Use a different tirofiban salt form (may avoid claim 2) |
| 3 |
Claim 2 with exact bolus |
tirofiban HCl bolus 25 μg/kg |
Use “about” but not exact 25 μg/kg (often still disputed) or adjust bolus per construction |
| 4 |
Claim 1 refined as dependent |
Infusion 12–72 hours |
Start infusion outside the claimed window |
| 5 |
Narrow infusion start window |
Infusion 18–72 hours |
Use infusion start <18 hours or other regimen |
| 6 |
Reduce ACS risk |
Same bolus/infusion as claim 1; therapeutic purpose is ACS-risk reduction |
Use different dosing; challenge patient-selection/purpose elements under evidence |
Key Takeaways
- U.S. Patent 6,770,660 is a dosing regimen method patent for tirofiban (or salt): bolus ~25 μg/kg plus IV infusion ~0.15 μg/kg/min for ~12–72 hours to inhibit platelet aggregation.
- Dependent claims further narrow to tirofiban hydrochloride and infusion windows including 18–72 hours.
- A parallel independent claim covers ACS risk reduction using the same regimen, enabling multiple therapeutic-purpose infringement theories.
- The enforceability and clearance strategy for generics or biosimilar-like competitors depends on whether their labeling and administered protocols track these numeric and timing limitations.
FAQs
- How do courts typically construe “about” in tirofiban dosing method patents with μg/kg and μg/kg/min units?
- If a protocol uses tirofiban without a bolus, does that avoid infringement of claim 1?
- Does selecting a different tirofiban salt form avoid claim 2 but still risk claim 1 infringement?
- What labeling language most strongly creates induced infringement risk for regimen patents like 6,770,660?
- If infusion duration is within 12–72 hours but infusion rate differs from 0.15 μg/kg/min, which claim limitations become easiest to attack?
References
- United States Patent 6,770,660.
